Their study systematically evaluated the efficacy of this granulysin-based immunotoxin, MFE23GRNLY, in HeLa-CEA tumor-bearing mice, providing the first proof-of-concept for its use in cancer therapy [221]. Here, GNLY is linked to neoplasm.